Organon & Co. (NYSE:OGN) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC reduced its holdings in Organon & Co. (NYSE:OGNGet Rating) by 1.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 82,733 shares of the company’s stock after selling 1,147 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Organon & Co. were worth $1,936,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vantage Consulting Group Inc increased its stake in Organon & Co. by 5.9% during the second quarter. Vantage Consulting Group Inc now owns 6,785 shares of the company’s stock worth $229,000 after acquiring an additional 377 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Organon & Co. by 6.4% during the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 6,340 shares of the company’s stock worth $214,000 after acquiring an additional 380 shares during the last quarter. Perigon Wealth Management LLC increased its stake in Organon & Co. by 5.9% during the second quarter. Perigon Wealth Management LLC now owns 6,962 shares of the company’s stock worth $235,000 after acquiring an additional 385 shares during the last quarter. Beacon Pointe Advisors LLC increased its stake in Organon & Co. by 4.1% during the second quarter. Beacon Pointe Advisors LLC now owns 10,804 shares of the company’s stock worth $362,000 after acquiring an additional 422 shares during the last quarter. Finally, Advisory Services Network LLC increased its stake in Organon & Co. by 2.1% during the second quarter. Advisory Services Network LLC now owns 21,301 shares of the company’s stock worth $719,000 after acquiring an additional 442 shares during the last quarter. 75.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OGN has been the subject of several research analyst reports. Morgan Stanley dropped their price target on Organon & Co. from $27.00 to $24.00 and set an “equal weight” rating for the company in a research note on Friday, November 4th. Bank of America downgraded Organon & Co. from a “neutral” rating to an “underperform” rating and set a $25.00 target price for the company. in a research report on Friday, October 14th.

Organon & Co. Price Performance

Shares of NYSE OGN opened at $32.06 on Friday. Organon & Co. has a 1-year low of $22.88 and a 1-year high of $39.47. The business has a 50-day moving average of $26.88 and a 200-day moving average of $28.18. The company has a market capitalization of $8.15 billion, a price-to-earnings ratio of 8.10 and a beta of 0.72.

Organon & Co. (NYSE:OGNGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.20. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a negative return on equity of 114.90% and a net margin of 16.07%. Research analysts expect that Organon & Co. will post 5.11 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 15th. Investors of record on Monday, November 14th were issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date of this dividend was Thursday, November 10th. Organon & Co.’s dividend payout ratio is currently 28.28%.

Organon & Co. Profile

(Get Rating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.

Recommended Stories

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNGet Rating).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.